HitGen and Biogen enter a DNA-Encoded Library-Based Drug Discovery Research Collaboration

HitGen and Biogen enter a DNA-Encoded Library-Based Drug Discovery Research Collaboration-中国成都先导与美国Biogen签订基于DNA编码化合物库技术的新药研发合作协议
Published on: November 21, 2018
Author: Editor

Hitgen Ltd announced that the company has entered into a drug discovery research collaboration with Biogen to identify novel small molecule leads for targets of interest. In this collaboration, HitGen will apply its technology platform, based on DNA-encoded library design, synthesis and interrogation, to discover novel leads which will be licensed exclusively to Biogen. Under the terms of the agreement, HitGen will receive upfront payments, and be eligible for milestone payments. Specific financial details were not disclosed.

“We are delighted to enter this collaboration with Biogen, a major research-based pharmaceutical company providing world-wide benefits to patients. This collaboration further emphasizes the role of HitGen in the rapidly developing field of DNA-encoded chemistry. We will work closely with Biogen scientists to generate new lead compounds for their research programmes to address unmet medical needs.” said Dr. Jin Li, Chairman of the Board and Chief Executive Officer of HitGen.

“We look forward to collaborating with HitGen to identify new small molecule leads from DNA-encoded libraries. Through this collaboration, we hope to advance drug candidates that could eventually translate into new treatment options for patients living with serious neurological conditions,” said Dr. Anabella Villalobos, senior vice president and head of Biotherapeutics and Medicinal Sciences at Biogen.

About HitGen Ltd

HitGen is a rapidly growing biotech company with headquarters and custom-built research facilities based in Chengdu, China, with a subsidiary based in Houston, TX USA. HitGen has established an industry-leading platform for early-stage drug discovery research centred on DNA encoded chemical libraries (DELs). HitGen’s DELs include encoded syntheses for more than 300 billion novel, diverse, drug-like small molecule and macrocycle compounds. These compounds are members of DELs synthesised from many hundreds of distinct chemical scaffolds, designed and assembled with tractable chemistry based on proven results for identifying drug-like leads against biological targets from known and novel classes. HitGen is working with multiple pharmaceutical and biotech companies, foundations and research institutes to discover and develop the novel therapeutics of the future.

Source: Biospace

China News Life Science Pharmaceutical